Anatara is pleased that activities for the March quarter progressed favourably and near to anticipated timelines. There appears to be a wider appreciation of Anatara's human health initiatives with a focus on using the restoration and/or maintenance of gastrointestinal tract harmony to improve overall wellbeing.
On 14 December 2020, Anatara Lifesciences Limited (ASX:ANR) announced details of an off-market share buy-back facility (Buy-Back Facility) to buyback all of the shares held by shareholders who held unmarketable parcels of shares in the Company.
Anatara Lifesciences (ASX:ANR) is pleased to advise that it is has received Human Research Ethics Committee (HREC) approval to undertake a clinical trial of its Gastrointestinal Re-Programming complementary medicine (GaRP) in participants with irritable bowel syndrome - diarrhoea subtype (IBS-D).
Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $888,049 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) tax incentive scheme.
Anatara Lifesciences (ASX:ANR) is pleased to announce successful completion of the poultry challenge trial "Efficacy of ANR-pf on the performance of broilers subject to subclinical and necrotic enteritis challenges".
Anatara Lifesciences (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2020. The Company's cash plus term deposits at the end of the quarter stood at $3.68m.
Nyrada Inc (ASX:NYR) is pleased to report encouraging efficacy results from its cholesterol-lowering drug program which is directed at developing an oral PCSK9 inhibitor treatment for hypercholesterolemia (high cholesterol).
